SLC22A9

Across TCGA pan-cancer cohorts, SLC22A9 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SLC22A9’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where SLC22A9 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC22A9 is over-expressed in tumor, although a few such as CHOL and KIRP show the opposite, repressed pattern.

CHOL, KIRP, and HNSC are the cancer types where SLC22A9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC22A9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	All	All	−3.337	<.001	3	view →
KIRP	Male	All	−0.175	.023	3	view →
HNSC	Male	III,IV	+0.120	.007	3	view →
LUSC	All	All	+0.065	.003	2	view →
KICH	All	III,IV	−0.327	.041	1	view →
THCA	Female	All	−0.016	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SLC22A9–CHOL

Open the CHOL breakdown →